HUMA
HUMA
NASDAQ · Biotechnology

Humacyte Inc

$0.46
+0.01 (+1.56%)
Financial Highlights (FY 2026)
Revenue
3.65M
Net Income
-72,981,270
Gross Margin
-376.0%
Profit Margin
-2,003.6%
Rev Growth
+17.4%
D/E Ratio
20.86
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -376.0% -376.0% 41.4% 41.4%
Operating Margin -6,398.6% -5,758.8% 4.5% 4.7%
Profit Margin -2,003.6% -1,903.4% 3.2% 3.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.65M 3.11M 180.17M 139.91M
Gross Profit -13,711,670 -11,681,436 74.60M 57.93M
Operating Income -233,309,150 -178,887,574 8.07M 6.54M
Net Income -72,981,270 -55,957,695 5.71M 4.80M
Gross Margin -376.0% -376.0% 41.4% 41.4%
Operating Margin -6,398.6% -5,758.8% 4.5% 4.7%
Profit Margin -2,003.6% -1,903.4% 3.2% 3.4%
Rev Growth +17.4% +17.4% +21.8% +16.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 59.41M 59.41M 75.78M 80.20M
Total Equity 2.85M 2.85M 156.42M 129.75M
D/E Ratio 20.86 20.86 0.48 0.62
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -219,933,100 -178,000,038 9.37M 7.10M
Free Cash Flow — — 5.00M 3.87M